PCM
OREX

Prelude Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Prelude Capital Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-220
Closed -$14K – 2443
2014
Q2 		$14K Buy
+220
New +$12.8K ﹤0.01% 1788

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Prelude Capital Management's OREX Position: Q4 2017 in Review

Prelude Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 7,800 shares — an estimated $17K sold.

Prelude Capital Management first reported a position in OREX in Q1 2015 and held it in 6 quarters. The position peaked at $59K in Q2 2015. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

  • Prelude Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Prelude Capital Management sold 7,800 Orexigen Therapeutics, Inc. shares in Q4 2017, an estimated $17K.
  • Prelude Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q1 2015 and held it in 6 quarters.
  • Prelude Capital Management's Orexigen Therapeutics, Inc. position peaked at $59K in Q2 2015.
  • 41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.